HOXB9 and colorectal carcinoma: Carbone et al. explored the prognostic role of HOXB9 in disease-free survival (DFS) and reported that HOXB9 expression was an independent adverse risk factor for worse DFS in stage IV CRC and possibly more important compared to KRAS and BRAF mutations, which are well-known negative prognostic markers in CRC/CRLM [29,33].